A practical reference on subcutaneous dosing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
=== Analgesic === Data from clinical trials have indicated that SNRIs might have pain-relieving properties. Although the perception and transmission of pain stimuli in the central nervous system have not been fully elucidated, extensive data support the roles of serotonin and norepinephrine in pain modulation. Findings from clinical trials in humans have shown that these antidepressants can help to reduce pain and functional impairment in central and neuropathic pain conditions. This property of SNRIs might be used to reduce doses of other pain relieving medication and lower the frequency of safety, limited efficacy, and tolerability issues. Clinical research data has shown that in patients with GAD, duloxetine is significantly more effective than placebo in reducing pain-related symptoms of GAD, after short-term and long-term treatment. However, findings suggested that such symptoms of physical pain recur in relapse situations, which indicate a need for ongoing treatment in patients with GAD and concurrent painful physical symptoms.
== Discovery and production == During the 1950s and 1960s, the National Cancer Institute carried out a wide-ranging program of screening plant and marine organism material. As part of that program, extract from the sea squirt Ecteinascidia turbinata was found to have anticancer activity in 1969. Separation and characterization of the active molecules had to wait many years for the development of sufficiently sensitive techniques, and the structure of one of them, Ecteinascidin 743, was determined by KL Rinehart at the University of Illinois in 1984. Rinehart had collected his sea squirts by scuba diving in the reefs of the West Indies. The biosynthetic pathway responsible for producing the drug has been determined to come from Candidatus Endoecteinascidia frumentensis, a microbial symbiont of the tunicate. The Spanish company PharmaMar licensed the compound from the University of Illinois before 1994 and attempted to farm the sea squirt with limited success. Yields from the sea squirt are extremely low as around 1,000 kilograms of animals is needed to isolate 1 gram of trabectedin - and about 5 grams were believed to be needed for a clinical trial so Rinehart asked the Harvard chemist E. J. Corey to search for a synthetic method of preparation. His group developed such a method and published it in 1996. This was later followed by a simpler and more tractable method which was patented by Harvard and subsequently licensed to PharmaMar.
As of 2025, the artificial intelligence (AI) market in the United Kingdom is worth over £21 billion, and is expected to exceed £1 trillion by 2035. It is the world's third-largest AI market and consistently ranked 3rd in private AI funding between 2013 and 2024, both behind the United States and China. The country ranked fifth globally in a 2024 report on AI development by Stanford University. In the first (2024) edition of GIRAI, the United Kingdom was ranked 4th out of 138 countries assessed and in the second (2026) edition, the country rank fell to 7th out of 135 countries. The UK AI market is valued at over £21 billion in 2025 and projected to exceed £1 trillion by 2035. The UK's prominence is rooted in a strong historical foundation, beginning with Alan Turing's theoretical work in the 1930s and 1940s, and the establishment of early AI research centres in the 1960s, such as those at the University of Edinburgh. Despite periods of reduced funding known as "AI winters", modern UK AI research has seen significant breakthroughs, most notably through London-based DeepMind's achievements in deep reinforcement learning and protein structure prediction. The UK AI sector has experienced rapid growth. The number of AI companies increased by 85% between 2022 and 2024, reaching 5,862 firms. In 2024, the sector generated an estimated £23.9 billion in revenue and £11.8 billion in Gross Value Added (GVA), employing over 86,000 people.
== History == In 1925, construction began on the current infectious diseases hospital building (the old pavilion) and the annex building (which now houses the hospital pharmacy). On 21 September 1932, the newly completed pavilion was designated for the treatment of patients with communicable diseases, including tuberculosis (TB). Prior to the opening of the new TB pavilion in 1942, the epidemic hospital operated with 50 beds for infectious diseases and 20 beds for TB patients. These 70 beds were attended to by four nurses, a sanitary officer, a disinfectant, and two maids. The doctors who served the newly established unit were: Dimitrie Preda (1932–1959), Alfred Metz (1932–1936 and 1947–1949), Tiberiu Micle (1939–1942), Dumitru Hortopan (1940–1947), Oliver Pop (1946–1962), and Laurențiu Cucuruz (1946–1989). Alfred Metz, as a secondary physician, laid the foundations of the clinical laboratory of the newly built hospital. From 1949 to 1969, Hans Röhrich served as the head of the infectious diseases hospital, where he established the first department of thoracic and lung surgery in Timișoara. The first lung segmentectomy was performed in 1958. Starting in 1961, thoracic surgery made significant progress in areas such as thoracic plastic surgery, pneumothorax, mediastinum, rib resection, and pericardium. Virgil Ene succeeded Hans Röhrich, taking over as head of the clinic in 1970. The growing demand for hospital space prompted the construction of a new pavilion. Construction started in 1971, and the pavilion was inaugurated on 1 July 1973.
Sources: en.wikipedia.org
SR-17018, also known informally as SR-17 or just SR and as 5,6-dichloro-desmethylchlorphine, is an atypical opioid receptor modulator with unusual actions and effects. It acts as a biased partial agonist of the μ-opioid receptor (MOR), showing strong selectivity for activation of G protein signaling over β-arrestin2 recruitment at this receptor. In addition, the drug appears to also act as a MOR positive allosteric modulator, with this possibly being its primary action. Unlike conventional opioids such as morphine and fentanyl, SR-17018 produces robust analgesic effects in rodents with very little respiratory depression and with much less analgesic tolerance. Moreover, substitution of conventional opioids like morphine with SR-17018 can reverse analgesic tolerance and suppress withdrawal symptoms in rodents. However, conflicting findings exist in terms of analgesic tolerance and respiratory depression. The drug has not been formally studied in humans. SR-17018 was first described in the scientific literature by Laura Bohn and colleagues in 2017. It was encountered online as a novel designer drug by 2023. Subsequently, discussion of SR-17018 on the social media website Reddit dramatically increased in 2024. Although technically a designer opioid, SR-17018 is said to have very different effects from other opioids, for instance producing minimal euphoria. Rather than being used recreationally itself, SR-17018 is typically employed by users to prevent opioid withdrawal symptoms and facilitate opioid discontinuation in the context of opioid dependence.
== Mechanism of action == Topotecan is a semi-synthetic derivative of camptothecin. Camptothecin is a natural product extracted from the bark of the tree Camptotheca acuminata. Topoisomerase-I is a nuclear enzyme that relieves torsional strain in DNA by opening single strand breaks. Once topoisomerase-I creates a single strand break, the DNA can rotate in front of the advancing replication fork. In physiological environments, topotecan is in equilibrium with its inactive carboxylate form. Topotecan's active lactone form intercalates between DNA bases in the topoisomerase-I cleavage complex. The binding of topotecan in the cleavage complex prevents topoisomerase-I from religating the nicked DNA strand after relieving the strain. This intercalation therefore traps the topoisomerase-I in the cleavage complex bound to the DNA. When the replication-fork collides with the trapped topoisomerase-I, DNA damage occurs. The unbroken DNA strand breaks and mammalian cells cannot efficiently repair these double strand breaks. The accumulation of trapped topoisomerase-I complexes is a known response to apoptotic stimuli. This disruption prevents DNA replication and ultimately leads to cell death. This process leads to breaks in the DNA strand resulting in apoptosis. Administration of topotecan down-regulates its target, topoisomerase-I; therefore, it is dosed to maximize efficacy and minimize related toxicity. Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer.
Thus, when the neuron is at a depolarized membrane potential, polyamines will block the AMPAR channel more strongly, preventing the flux of potassium ions through the channel pore. GluA2-lacking AMPARs are, thus, said to have an inwardly rectifying I/V curve, which means that they pass less outward current than inward current at equivalent distance from the reversal potential. Calcium permeable AMPARs are found typically early during postnatal development on neocortical pyramidal neurons, some interneurons, or in dopamine neurons of the ventral tegmental area after the exposure to an addictive drug. Alongside RNA editing, alternative splicing allows a range of functional AMPA receptor subunits beyond what is encoded in the genome. In other words, although one gene (GRIA1–GRIA4) is encoded for each subunit (GluA1–GluA4), splicing after transcription from DNA allows some exons to be translated interchangeably, leading to several functionally different subunits from each gene. The flip/flop sequence is one such interchangeable exon. A 38-amino acid sequence found prior to (i.e., before the N-terminus of) the fourth membranous domain in all four AMPAR subunits, it determines the speed of desensitization of the receptor and also the speed at which the receptor is resensitized and the rate of channel closing. The flip form is present in prenatal AMPA receptors and gives a sustained current in response to glutamate activation.
Adanson (1763), de Jussieu (1789), and Candolle (1819) all proposed various alternative natural systems of classification that grouped plants using a wider range of shared characters and were widely followed. The Candollean system reflected his ideas of the progression of morphological complexity and the later Bentham & Hooker system, which was influential until the mid-19th century, was influenced by Candolle's approach. Darwin's publication of the Origin of Species in 1859 and his concept of common descent required modifications to the Candollean system to reflect evolutionary relationships as distinct from mere morphological similarity. In the 19th century botany was a socially acceptable hobby for upper-class women. These women would collect and paint flowers and plants from around the world with scientific accuracy. The paintings were used to record many species that could not be transported or maintained in other environments. Marianne North illustrated over 900 species in extreme detail with watercolour and oil paintings. Her work and many other women's botany work was the beginning of popularising botany to a wider audience. Botany was greatly stimulated by the appearance of the first "modern" textbook, Matthias Schleiden's Grundzüge der Wissenschaftlichen Botanik, published in English in 1849 as Principles of Scientific Botany.
Since then, the species name Naja/Hoplocephalus bungaroides, originally coined for the king cobra and improperly assigned to the broad-headed snake, became conflated with the broad-headed snake and used as the type species of Hoplocephalus, while the species name Naja bungarus was treated as a junior synonym of the king cobra (until its revival as the species name for the Sunda king cobra in 2024). This longstanding discrepancy, which breaks the principle of priority, was overlooked for nearly two centuries and only discovered in 2024. Due to the long presence of the names Ophiophagus hannah and Hoplocephalus bungaroides in the literature, which would be upended if these two species were reclassified based on this issue, it was decided to maintain the longstanding scientific names for both taxa and designate a new, accurate type specimen for the broad-headed snake.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。